Read-Gene S.A.

Equities

RDG

PLRADGN00014

Biotechnology & Medical Research

End-of-day quote Warsaw S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
4.74 ^PLN	+0.42%		-0.84%	-18.28%

14/05	Read-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
12/02	Read-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Read-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2022

February 10, 2023 at 02:17 pm IST

Read-Gene S.A. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was PLN 0.316967 million compared to net income of PLN 0.342544 million a year ago.

Latest news about Read-Gene S.A.

Read-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Read-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/02	CI
Read-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	12/02	CI
Read-Gene S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Read-Gene S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Read-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Read-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10	CI
Read-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	10/23/10	CI
Read-Gene S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Read-Gene S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Read-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Read-Gene S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	11/22/11	CI
Read-Gene S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/21/15	CI
Read-Gene S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	15/21/15	CI
Read-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	16/21/16	CI

Chart Read-Gene S.A.

Duration

Period

More charts

Company Profile

Read-Gene SA is a Poland-based company active in the biotechnology sector. It is focused on technologies which aim is to detect, prevent and treat malignant tumors. The Company specializes in three fields: chemoprevention, clinical trials and genetic testing. It offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The Company operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
READ-GENE S.A.	-18.28%	14.18M
EXACT SCIENCES CORPORATION	-38.56%	8.39B
GUARDANT HEALTH, INC.	+0.18%	3.32B
IOVANCE BIOTHERAPEUTICS, INC.	+9.29%	2.48B
BGI GENOMICS CO., LTD.	-18.21%	2.06B
VERACYTE, INC.	-24.57%	1.59B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+32.37%	1.15B
SEEGENE, INC.	-7.64%	704M
CAREDX, INC	+8.42%	678M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.59%	508M

Bio Diagnostics & Testing